All In Biotech

Drug Trial Radar · NCT03304054

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

93

Actual

Start

Apr 18, 2018

Primary completion

Jan 31, 2020

Study completion Mar 15, 2020

Sponsor

Lead sponsor
Catalyst Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.

Conditions

  • Myasthenia Gravis, Generalized

Interventions

  • Amifampridine PhosphateDrug

    tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day

  • Placebo Oral TabletDrug

    tablets matching amifampridine phosphate, 3 to 4 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myasthenia Gravis-Activities of Daily Living (MG-ADL) Summary by Time Point and Myasthenia Gravis Type: Wilcoxon-Mann-Whitney Rank Sum Test ResultsTime frame: Last day (Day 0) of the Run-in period and at the post-treatment visit (i.e., day 10 or the time point at which a patient discontinued treatment early).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio

  • Univerity of Pennsylvania

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.